Search

Your search keyword '"Chien, R."' showing total 17 results
Start Over Author "Chien, R." Publisher wiley
17 results on '"Chien, R."'

1. The present and future disease burden of hepatitis C virus infections with today's treatment paradigm: Volume 4

Author

Chan, H. L. Y., primary, Chen, C. J., additional, Omede, O., additional, Al Qamish, J., additional, Al Naamani, K., additional, Bane, A., additional, Tan, S. S., additional, Simonova, M., additional, Cardenas, I., additional, Derbala, M., additional, Akin, O., additional, Phillips, R. O., additional, Abdelmageed, M. K., additional, Abdulla, M., additional, Adda, D., additional, Al Baqali, A., additional, Al Dweik, N., additional, Al Ejji, K., additional, Al ghazzawi, I., additional, Al Kaabi, S., additional, Al Sadadi, M., additional, Al Salman, J., additional, AlBadri, M., additional, Al-Busafi, S. A., additional, Al-Romaihi, H. E., additional, Ampofo, W., additional, Antonov, K., additional, Anyaike, C., additional, Arome, F., additional, Blach, S., additional, Borodo, M. M., additional, Brandon, S. M., additional, Bright, B., additional, Butt, M. T., additional, Chen, D. S., additional, Chen, P. J., additional, Chien, R. N., additional, Chuang, W. L., additional, Cuellar, D., additional, Elbardiny, A. A., additional, Estes, C., additional, Farag, E., additional, Fung, J., additional, Gamkrelidze, I., additional, Garcia, V., additional, Genov, J., additional, Ghandour, Z., additional, Ghuloom, M., additional, Gomez, B., additional, Gunter, J., additional, Habeeb, J., additional, Hajelssedig, O., additional, Hamoudi, W., additional, Himatt, S. M., additional, Hrstic, I., additional, Hu, C. C., additional, Huang, C. F., additional, Hui, Y. T., additional, Jahis, R., additional, Jelev, D., additional, John, A. K., additional, Kaliaskarova, K. S., additional, Kamel, Y., additional, Kao, J. H., additional, Khamis, J., additional, Khattabi, H., additional, Khoudri, I., additional, Konysbekova, A., additional, Kotzev, I., additional, Lai, M. S., additional, Lao, W. C., additional, Layden, J., additional, Lee, M. H., additional, Lesi, O., additional, Li, M., additional, Lo, A., additional, Loo, C. K., additional, Lukšić, B., additional, Maaroufi, A., additional, Malu, A. O., additional, Mateva, L., additional, Mitova, R., additional, Mohamed, R., additional, Morović, M., additional, Murphy, K., additional, Mustapha, B., additional, Nersesov, A., additional, Ngige, E., additional, Njouom, R., additional, Njoya, O., additional, Nonković, D., additional, Obekpa, S., additional, Oguche, S., additional, Okolo, E. E., additional, Omuemu, C., additional, Ondoa, P., additional, Opare-Sem, O., additional, Owusu-Ofori, S., additional, Prokopenko, Y. N., additional, Razavi, H., additional, Razavi-Shearer, D., additional, Razavi-Shearer, K., additional, Redae, B., additional, Reic, T., additional, Rinke de Wit, T., additional, Rios, C., additional, Robbins, S., additional, Roberts, L. R., additional, Sanad, S. J., additional, Schmelzer, J. D., additional, Sharma, M., additional, Su, T. H., additional, Sultan, K., additional, Tchernev, K., additional, Tsang, O. T. Y., additional, Tsang, S., additional, Tzeuton, C., additional, Ugoeze, S., additional, Uzochukwu, B., additional, Vi, R., additional, Vince, A., additional, Wani, H. U., additional, Wong, V. W. S., additional, Workneh, A., additional, Yacoub, R., additional, Yesmembetov, K. I., additional, Youbi, M., additional, Yuen, M. F., additional, and Nde, H., additional

Published
2017
Full Text
View/download PDF

2. Strategies to manage hepatitis C virus infection disease burden—Volume 4

Author

Chen, D. S., primary, Hamoudi, W., additional, Mustapha, B., additional, Layden, J., additional, Nersesov, A., additional, Reic, T., additional, Garcia, V., additional, Rios, C., additional, Mateva, L., additional, Njoya, O., additional, Al‐Busafi, S. A., additional, Abdelmageed, M. K., additional, Abdulla, M., additional, Adda, D., additional, Akin, O., additional, Al Baqali, A., additional, Al Dweik, N., additional, Al Ejji, K., additional, Al ghazzawi, I., additional, Al Kaabi, S., additional, Al Naamani, K., additional, Al Qamish, J., additional, Al Sadadi, M., additional, Al Salman, J., additional, AlBadri, M., additional, Al‐Romaihi, H. E., additional, Ampofo, W., additional, Antonov, K., additional, Anyaike, C., additional, Arome, F., additional, Bane, A., additional, Blach, S., additional, Borodo, M. M., additional, Brandon, S. M., additional, Bright, B., additional, Butt, M. T., additional, Cardenas, I., additional, Chan, H. L. Y., additional, Chen, C. J., additional, Chen, P. J., additional, Chien, R. N., additional, Chuang, W. L., additional, Cuellar, D., additional, Derbala, M., additional, Elbardiny, A. A., additional, Estes, C., additional, Farag, E., additional, Fung, J., additional, Gamkrelidze, I., additional, Genov, J., additional, Ghandour, Z., additional, Ghuloom, M., additional, Gomez, B., additional, Gunter, J., additional, Habeeb, J., additional, Hajelssedig, O., additional, Himatt, S. M., additional, Hrstic, I., additional, Hu, C. C., additional, Huang, C. F., additional, Hui, Y. T., additional, Jahis, R., additional, Jelev, D., additional, John, A. K., additional, Kaliaskarova, K. S., additional, Kamel, Y., additional, Kao, J. H., additional, Khamis, J., additional, Khattabi, H., additional, Khoudri, I., additional, Konysbekova, A., additional, Kotzev, I., additional, Lai, M. S., additional, Lao, W. C., additional, Lee, M. H., additional, Lesi, O., additional, Li, M., additional, Lo, A., additional, Loo, C. K., additional, Lukšić, B., additional, Maaroufi, A., additional, Malu, A. O., additional, Mitova, R., additional, Mohamed, R., additional, Morović, M., additional, Murphy, K., additional, Nde, H., additional, Ngige, E., additional, Njouom, R., additional, Nonković, D., additional, Obekpa, S., additional, Oguche, S., additional, Okolo, E. E., additional, Omede, O., additional, Omuemu, C., additional, Ondoa, P., additional, Opare‐Sem, O., additional, Owusu‐Ofori, S., additional, Phillips, R. O., additional, Prokopenko, Y. N., additional, Razavi, H., additional, Razavi‐Shearer, D., additional, Razavi‐Shearer, K., additional, Redae, B., additional, Rinke de Wit, T., additional, Robbins, S., additional, Roberts, L. R., additional, Sanad, S. J., additional, Sharma, M., additional, Simonova, M., additional, Su, T. H., additional, Sultan, K., additional, Tan, S. S., additional, Tchernev, K., additional, Tsang, O. T. Y., additional, Tsang, S., additional, Tzeuton, C., additional, Ugoeze, S., additional, Uzochukwu, B., additional, Vi, R., additional, Vince, A., additional, Wani, H. U., additional, Wong, V. W. S., additional, Workneh, A., additional, Yacoub, R., additional, Yesmembetov, K. I., additional, Youbi, M., additional, Yuen, M. F., additional, and Schmelzer, J. D., additional

Published
2017
Full Text
View/download PDF

3. Historical epidemiology of hepatitis C virus in select countries-volume 4

Author

Maaroufi, A., primary, Vince, A., additional, Himatt, S. M., additional, Mohamed, R., additional, Fung, J., additional, Opare-Sem, O., additional, Workneh, A., additional, Njouom, R., additional, Al ghazzawi, I., additional, Abdulla, M., additional, Kaliaskarova, K. S., additional, Owusu-Ofori, S., additional, Abdelmageed, M. K., additional, Adda, D., additional, Akin, O., additional, Al Baqali, A., additional, Al Dweik, N., additional, Al Ejji, K., additional, Al Kaabi, S., additional, Al Naamani, K., additional, Al Qamish, J., additional, Al Sadadi, M., additional, Al Salman, J., additional, AlBadri, M., additional, Al-Busafi, S. A., additional, Al-Romaihi, H. E., additional, Ampofo, W., additional, Antonov, K., additional, Anyaike, C., additional, Arome, F., additional, Bane, A., additional, Blach, S., additional, Borodo, M. M., additional, Brandon, S. M., additional, Bright, B., additional, Butt, M. T., additional, Cardenas, I., additional, Chan, H. L. Y., additional, Chen, C. J., additional, Chen, D. S., additional, Chen, P. J., additional, Chien, R. N., additional, Chuang, W. L., additional, Cuellar, D., additional, Derbala, M., additional, Elbardiny, A. A., additional, Estes, C., additional, Farag, E., additional, Gamkrelidze, I., additional, Garcia, V., additional, Genov, J., additional, Ghandour, Z., additional, Ghuloom, M., additional, Gomez, B., additional, Gunter, J., additional, Habeeb, J., additional, Hajelssedig, O., additional, Hamoudi, W., additional, Hrstic, I., additional, Hu, C. C., additional, Huang, C. F., additional, Hui, Y. T., additional, Jahis, R., additional, Jelev, D., additional, John, A. K., additional, Kamel, Y., additional, Kao, J. H., additional, Khamis, J., additional, Khattabi, H., additional, Khoudri, I., additional, Konysbekova, A., additional, Kotzev, I., additional, Lai, M. S., additional, Lao, W. C., additional, Layden, J., additional, Lee, M. H., additional, Lesi, O., additional, Li, M., additional, Lo, A., additional, Loo, C. K., additional, Lukšić, B., additional, Malu, A. O., additional, Mateva, L., additional, Mitova, R., additional, Morović, M., additional, Murphy, K., additional, Mustapha, B., additional, Nde, H., additional, Nersesov, A., additional, Ngige, E., additional, Njoya, O., additional, Nonković, D., additional, Obekpa, S., additional, Oguche, S., additional, Okolo, E. E., additional, Omede, O., additional, Omuemu, C., additional, Ondoa, P., additional, Phillips, R. O., additional, Prokopenko, Y. N., additional, Razavi, H., additional, Razavi-Shearer, D., additional, Redae, B., additional, Reic, T., additional, Rinke de Wit, T., additional, Rios, C., additional, Robbins, S., additional, Roberts, L. R., additional, Sanad, S. J., additional, Schmelzer, J. D., additional, Sharma, M., additional, Simonova, M., additional, Su, T. H., additional, Sultan, K., additional, Tan, S. S., additional, Tchernev, K., additional, Tsang, O. T. Y., additional, Tsang, S., additional, Tzeuton, C., additional, Ugoeze, S., additional, Uzochukwu, B., additional, Vi, R., additional, Wani, H. U., additional, Wong, V. W. S., additional, Yacoub, R., additional, Yesmembetov, K. I., additional, Youbi, M., additional, Yuen, M. F., additional, and Razavi-Shearer, K., additional

Published
2017
Full Text
View/download PDF

14. Comparison of the once-daily levofloxacin-containing triple therapy with the twice-daily standard triple therapy for first-line Helicobacter pylori eradication: a prospective randomised study.

Author

Chen LW, Chien RN, Chang JJ, Fang KM, and Chang LC

Subjects
Adult, Aged, Amoxicillin administration & dosage, Anti-Bacterial Agents adverse effects, Anti-Ulcer Agents administration & dosage, Clarithromycin administration & dosage, Drug Administration Schedule, Drug Therapy, Combination methods, Esomeprazole administration & dosage, Female, Humans, Male, Middle Aged, Ofloxacin adverse effects, Prospective Studies, Treatment Outcome, Anti-Bacterial Agents administration & dosage, Helicobacter Infections prevention & control, Helicobacter pylori, Levofloxacin, Ofloxacin administration & dosage
Abstract

Background/aims: Simple compound of Helicobacter pylori eradication therapy may improve drug compliance of patients. The aims of this study were to compare the efficacy and tolerability of a simple combination containing levofloxacin 7-day once-daily with standard twice-daily triple therapy., Patients and Methods: This was a prospective, randomised, open-label trial. A total of 189 consecutive patients diagnosed with peptic ulcer and H. pylori infection were enrolled. Patients were randomly divided into two groups: LEC group--levofloxacin 500 mg, esomeprazole 40 mg and clarithromycin 500 mg once daily for 7 days; AEC group--amoxicillin 1 g, esomeprazole 40 mg and clarithromycin 500 mg twice daily for 7 days., Results: There were 90 patients in the LEC group and 99 patients in the AEC group. By intention-to-treat and per-protocol analysis, the H. pylori eradication rate was 78.9% [71/90; 95% confidence interval (CI), 70.3-87.5%] and 83.5% (71/85; 95% CI, 75.5-91.6%) respectively, in the LEC group; and 74.8% (74/99; 95% CI, 66.0-83.5%) and 86.0% (74/86; 95% CI, 78.6-93.5%) respectively, in the AEC group. The incidence and tolerability of side effects were similar between these two groups., Conclusion: The efficacy and tolerability of once-daily levofloxacin-containing triple therapy are equal to those of the standard twice-daily triple therapy in this study. However, none of the treatment regimens evaluated achieved enough eradication efficacies to be considered as a recommendable first-line treatment., (© 2010 Blackwell Publishing Ltd.)

Published
2010
Full Text
View/download PDF

15. Solitary actinomycotic abscesses of liver: report of two cases.

Author

Chen LW, Chang LC, Shie SS, and Chien RN

Subjects
Actinomycosis diagnosis, Actinomycosis drug therapy, Administration, Oral, Aged, Diagnosis, Differential, Female, Humans, Infusions, Intravenous, Liver Abscess diagnosis, Liver Abscess drug therapy, Liver Neoplasms diagnosis, Male, Penicillins administration & dosage, Actinomycosis complications, Liver Abscess microbiology
Abstract

Hepatic actinomycotic abscesses are rare and secondary to other intra-abdominal infections. History of intra-abdominal surgery is a principal contributing factor for the abscess formation. Patients with hepatic actinomycotic abscess may suffer from fever, malaise, abdominal pain and bodyweight loss. The clinical progress of actinomycotic abscess is more indolent than the usual course of other pyogenic abscess. It is sometimes diagnosed as malignancy. This report consists of two cases of hepatic actinomycotic abscess mimicking tumours. Laboratory data revealed elevated alkaline phosphatase and leucocytosis. The abdominal computed tomography scan showed multiloculated lesions with peripheral contrast enhancement appearance. Diagnosis confirmation was based on the typical histologic feature of sulfur granules with inflammatory process by echo-guided fine needle biopsy or surgical specimen. These two cases were resolved with extended courses of intravenous and oral penicillin treatment.

Published
2006
Full Text
View/download PDF

16. Acute leukaemia in chronic hepatitis B patients with lamivudine therapy.

Author

Chien RN, Yeh CT, Wang PN, Kuo MC, Hsieh SY, Shih LY, and Liaw YF

Subjects
Acute Disease, Adult, Female, Humans, Male, Middle Aged, Hepatitis B, Chronic drug therapy, Lamivudine adverse effects, Leukemia, Myeloid chemically induced, Reverse Transcriptase Inhibitors adverse effects
Abstract

Extensive clinical data have shown that lamivudine is an effective and safe drug for patients with chronic hepatitis B virus infection. No significant serious side effect has been reported. Four hundred and forty-eight patients with chronic hepatitis B, treated with lamivudine for more than 6 months, were closely monitored. Two patients developed acute myeloid leukaemia during or after lamivudine therapy. The first case developed acute myeloid leukaemia, 1 year after stopping lamivudine therapy, when A529T mutant HBV-DNA was still detectable. The second case achieved complete virological response but suffered from acute myeloid leukaemia during the ninth month of lamivudine treatment. D553N mutant hepatitis B virus was detected in granulocytes of her peripheral blood. Based on our lamivudine therapy data, the calculated incidence of acute myeloid leukaemia in patients during or after lamivudine therapy was higher in males and females than that of the general population. Whether lamivudine-selected viral mutations have enhanced activity/production of transcriptional transactivator and thereby increased the chance of leukaemic transformation of haematopoietic progenitor cells deserves further investigation.

Published
2004
Full Text
View/download PDF

17. Unintentional rechallenge resulting in a causative relationship between ketoconazole and acute liver injury.

Author

Chien RN, Sheen IS, and Liaw YF

Subjects
Acute Disease, Biopsy, Needle methods, Female, Humans, Middle Aged, Necrosis, Recurrence, Antifungal Agents adverse effects, Chemical and Drug Induced Liver Injury etiology, Ketoconazole adverse effects, Liver pathology
Abstract

We present the case of a female patient in whom acute overt hepatitis developed after 60 days of ketoconazole administration (200 mg/day). A prompt renewed hepatic injury 48 hours after an unintentional rechallenge 30 months later provided definitive evidence for a causative relationship between ketoconazole and acute liver injury. Histological examination revealed acute hepatitis with bridging hepatic necrosis. Clinicians should be aware of this cause and effect relationship between ketoconazole and acute liver injury, which can result in prompt severe acute liver injury after rechallenge.

Published
2003

Catalog

Books, media, physical & digital resources
See catalog results